Ginkgo to acquire Bayer's 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs
BOSTON , July 25, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the signing of a definitive agreement for the previously announced transaction with Bayer to expand Ginkgo's platform capabilities in agricultural biologicals. These capabilities will be built pursuant to a transaction in which Ginkgo will acquire Bayer's 175,000-square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform for approximately $83.0 million in consideration. The proposed transaction is projected to close in the fourth quarter of 2022, subject to regulatory approvals and customary closing conditions. Ginkgo will also integrate the R&D platform assets from Joyn Bio , a joint-venture between Ginkgo and Leaps by Bayer formed in 2017.
While chemical and plant trait products are currently the dominant offerings on the market to improve crop performance, agricultural biologicals are a rapidly growing category of solutions that have the potential to offer tremendous sustainability and performance benefits. Bayer will be the first major partner of Ginkgo's expanded agricultural biologicals platform, entering into a new collaboration focused on the advancement of Joyn's marquee nitrogen fixation program, as well as new programs in areas such as crop protection and carbon sequestration.
As part of a three-year strategic partnership, Ginkgo will provide research services to Bayer in the field of agricultural biologicals with the potential to earn downstream value in the form of royalties on net sales from products developed under the partnership. As previously disclosed, it is expected that the cash proceeds from this collaboration with Bayer will significantly offset the operating expenses acquired through the transaction. In addition to this collaboration with Bayer, Ginkgo expects to engage with other customers in supporting the development of their agricultural biological programs.
"To ensure sustainable food security for an ever growing population, we need to invest in biological solutions," said Jason Kelly , CEO and co-founder of Ginkgo Bioworks. "By acquiring one of the premier R&D sites for agricultural biologicals worldwide and partnering with the best-in-class teams at Bayer and Joyn, we are demonstrating our commitment to developing breakthrough products for growers around the world. We are excited to be able to make this platform accessible to innovative companies and teams who may otherwise not have the resources or expertise to develop these capabilities in house."
"Through this strategic research partnership with Ginkgo and by tapping into the open innovation ecosystem, Bayer is accelerating innovation in our biologicals pipeline and continuing to lead in the development of effective and reliable solutions," said Bob Reiter , Head of R&D for Bayer's Crop Science Division. "Agricultural biologicals have the potential to boost crop yields while simultaneously offering environmental benefits to growers, and Ginkgo's technologies will help to deliver on biologicals' potential."
About Ginkgo Bioworks Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Ginkgo's expectations regarding its ability to expand its platform capabilities in agricultural biologicals through the transaction, the expected timeline, potential outcomes and expected benefits of the transaction, Bayer's role as Ginkgo's first major partner in its expanded agricultural biologicals platform, the terms and scope of Ginkgo's ongoing collaboration with Bayer and its expectations with respect to the collaboration, and Ginkgo's expectations with respect to its ability to engage with other customers and partners through its agricultural biologicals platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: ( i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, ( iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, ( v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, ( vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of Ginkgo's COVID-19 testing business, (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations; (ix) the risk that the proposed transaction may not be completed in a timely manner or at all; ( x) the failure to satisfy any of the conditions to the consummation of the proposed transaction; ( xi) the risk that any regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; ( xii) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction; ( xiii) Ginkgo's ability to effectively integrate Bayer's existing Research & Development site, team and platform and its ability to integrate the R&D platform assets from Joyn Bio; ( xiv) the risk that operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers and suppliers) may be greater than expected, ( xv) the assumption of unexpected risks and liabilities; and ( xvi) the diversion of and attention of management on transaction-related issues. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT: investors@ ginkgobioworks. com
GINKGO BIOWORKS MEDIA CONTACT: press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-and-bayer-sign-definitive-agreement-to-build-agricultural-biologicals-rd-platform-capabilities-301592174.html
Today we will run through one way of estimating the intrinsic value of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) by...
Investors are trying to make sense of the markets, in face of conflicting signals. Year-to-date, we’re facing deep losses – but more recently, a sharp rally despite this week’s confirmation that we’re in a recession. Government data released on Thursday showed a 0.9% GDP contraction in Q2, which came on the heels of a 1.6% contraction in Q1. That’s two quarters in a row, the definition of a recession. Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program, reminds us the ‘conventional wis
Slaying the inflation dragon isn't done with baby steps. Expect much higher interest rates as a headwind for equities.
Looking to buy the dip? Start here.
Shares of the Illinois-based drugmaker AbbVie (NYSE: ABBV) were down by a hefty 5% as of 2:32 p.m. ET Friday afternoon. As a result, the Dividend Aristocrat's market capitalization has slipped by a staggering $13.2 billion today. Ahead of the opening bell, AbbVie announced its 2022 second-quarter earnings.
NEW YORK—The U.S. Securities and Exchange Commission on Friday added Alibaba Group Holding to a list of Chinese companies at risk of being delisted from the U.S. exchanges if their auditors can’t be inspected before spring 2024. The move comes days after Alibaba said it would apply for a primary listing in Hong Kong, where it obtained a secondary listing in 2019. Securing a primary listing in the Asian financial hub would allow Alibaba’s shares to continue to be traded even if it is booted from the American bourse.
The stock market is down so far this year; despite a rally since mid-June, the S&P is still down 15% year-to-date and the NASDAQ is down 23%. Share price drops like these get investors thinking about portfolio defense, and that naturally brings them around to dividend stocks. Companies can pay out dividends annually, quarterly, or monthly. Quarterly payments are the most common, but for truly defensive investors, monthly payments offer some advantages. Chief among those is the rapid and regular
It is now guiding for third-quarter revenue of $15 billion-$16 billion vs. the $18.67 billion consensus. As for full-year 2022, its EPS expectation is now $2.30, down from its prior forecast of $3.60 and the $3.39 consensus. In terms of revenue for the year, Intel now expects $65 billion-$68 billion, down from $76 billion and well below the $74.4 billion consensus.
After dropping for the first 5 ½ months of the year, the S&P 500 has rebounded 8.5% since June 15 and 4.7% since July 26, the day before the Federal Reserve raised interest rates. Investors have turned enthusiastic toward stocks partly because Fed Chairman Jerome Powell said after the rate hike that the central bank will eventually slow its rate hike campaign. Never mind that the Fed said in its statement announcing the rate increase that it "anticipates that ongoing increases in the target range [for the federal funds rate] will be appropriate."
Yahoo Finance markets reporter Alexandra Semenova details the losses Cathie Wood's ARK ETF is seeing amid Roku's earnings miss, Teledoc investments, and sale of Coinbase shares.
(Bloomberg) -- Investors should stay wary of US stocks and bonds as inflation remains a threat and recession looms, according to Rebecca Patterson, chief investment strategist at Bridgewater Associates.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekShock July Stock Rally Was a Monster the Fed May Regret SeeingAlito Decries 'Hostility to Religion' in First Public Remarks Since Abortion Decision Monkeypox is Spreading Fast. Now Kids Are Getting It, TooRockst
(Bloomberg) -- Jack Ma is taking a weeks-long tour in Europe after largely disappearing from public view for almost two years, adding to signs that China’s government is easing pressure on the entrepreneur as he steps back from a business empire that had made him one of the country’s most powerful people.Most Read from BloombergRockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooBiden, Xi Plan In-Person Meet as Taiwan Tensions IntensifyUS Economy Shrinks for a Second Quarte
British American Tobacco p.l.c.'s ( LON:BATS ) investors are due to receive a payment of £0.5445 per share on 10th of...
Alibaba Group Holding has been added to a growing list of Chinese companies that face potential delisting from US stock exchanges, days after the e-commerce giant announced plans to seek a primary listing on Hong Kong's bourse with the aim to diversify its investor base. The US Securities and Exchange Commission (SEC) on Friday included Alibaba, owner of the South China Morning Post, to its watch list of US-listed Chinese firms that face removal from American exchanges under a 2020 law, the Hold
Each of these five real estate investment trusts (REITs) currently pays a dividend of greater than 5%. For those willing to accept the risks, that’s a better yield than that of the U. S. Government 10-Year Treasury Note. Each REIT trades on the New York Stock Exchange, so plenty of information on these REITs is available from analysts at respected investment firms. Looking for ways to boost your returns? Check out Benzinga's coverage on Alternative Real Estate Investments: Exclusive Offering For
See who joins GOOGL on this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.
Apple delivered better-than-expected earnings and shares are now up 25% from the June low. Here's how to trade it from here.
Ford Motor lifted its quarterly dividend to 15 cents a share, a 50% boost, while Hershey raised its payout by 15%.
(Bloomberg) -- Alibaba Group Holding Ltd. has moved a step closer toward getting booted off US stock exchanges for American inspectors not being able to access to financial audits.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekAlito Decries 'Hostility to Religion' in First Public Remarks Since Abortion Decision Rockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooBiden, Xi Plan In-Person Meet as Taiwan Tensions IntensifyEuro-Zone Infla
If you still think you can't find winning stocks in the S&P 500, you're not looking hard enough.